Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”
EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival.
Gespeichert in:
| Autor*in: |
Schöffski, Patrick [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
15 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study - Hamzah, N. ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:152 ; year:2021 ; pages:26-40 ; extent:15 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejca.2021.04.015 |
|---|
| Katalog-ID: |
ELV054658233 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV054658233 | ||
| 003 | DE-627 | ||
| 005 | 20230624213145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2021.04.015 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica |
| 035 | |a (DE-627)ELV054658233 | ||
| 035 | |a (ELSEVIER)S0959-8049(21)00246-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Schöffski, Patrick |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” |
| 264 | 1 | |c 2021 | |
| 300 | |a 15 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. | ||
| 650 | 7 | |a Chemotherapy |2 Elsevier | |
| 650 | 7 | |a Tyrosine kinase inhibitor |2 Elsevier | |
| 650 | 7 | |a Ifosfamide |2 Elsevier | |
| 650 | 7 | |a Soft tissue sarcoma |2 Elsevier | |
| 650 | 7 | |a Nintedanib |2 Elsevier | |
| 650 | 7 | |a Oral anticancer treatment |2 Elsevier | |
| 650 | 7 | |a Vascular endothelial growth factor receptor |2 Elsevier | |
| 650 | 7 | |a Fibroblast growth factor receptor |2 Elsevier | |
| 700 | 1 | |a Toulmonde, Maud |4 oth | |
| 700 | 1 | |a Estival, Anna |4 oth | |
| 700 | 1 | |a Marquina, Gloria |4 oth | |
| 700 | 1 | |a Dudzisz-Śledź, Monika |4 oth | |
| 700 | 1 | |a Brahmi, Mehdi |4 oth | |
| 700 | 1 | |a Steeghs, Neeltje |4 oth | |
| 700 | 1 | |a Karavasilis, Vasilios |4 oth | |
| 700 | 1 | |a de Haan, Jacco |4 oth | |
| 700 | 1 | |a Wozniak, Agnieszka |4 oth | |
| 700 | 1 | |a Cousin, Sophie |4 oth | |
| 700 | 1 | |a Domènech, Marta |4 oth | |
| 700 | 1 | |a Bovée, Judith V.M.G. |4 oth | |
| 700 | 1 | |a Charon-Barra, Céline |4 oth | |
| 700 | 1 | |a Marreaud, Sandrine |4 oth | |
| 700 | 1 | |a Litière, Saskia |4 oth | |
| 700 | 1 | |a De Meulemeester, Laura |4 oth | |
| 700 | 1 | |a Olungu, Christine |4 oth | |
| 700 | 1 | |a Gelderblom, Hans |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Hamzah, N. ELSEVIER |t The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000241849 |
| 773 | 1 | 8 | |g volume:152 |g year:2021 |g pages:26-40 |g extent:15 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2021.04.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 152 |j 2021 |h 26-40 |g 15 | ||
| author_variant |
p s ps |
|---|---|
| matchkey_str |
schffskipatricktoulmondemaudestivalannam:2021----:admsdhs2tdcmaighefccadaeyfhoatrsnknsihbtritdnbihigegniofmdiptetwtavneioealmtsaisftsus |
| hierarchy_sort_str |
2021 |
| bklnumber |
44.52 |
| publishDate |
2021 |
| allfields |
10.1016/j.ejca.2021.04.015 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica (DE-627)ELV054658233 (ELSEVIER)S0959-8049(21)00246-X DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Schöffski, Patrick verfasserin aut Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” 2021 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Elsevier Toulmonde, Maud oth Estival, Anna oth Marquina, Gloria oth Dudzisz-Śledź, Monika oth Brahmi, Mehdi oth Steeghs, Neeltje oth Karavasilis, Vasilios oth de Haan, Jacco oth Wozniak, Agnieszka oth Cousin, Sophie oth Domènech, Marta oth Bovée, Judith V.M.G. oth Charon-Barra, Céline oth Marreaud, Sandrine oth Litière, Saskia oth De Meulemeester, Laura oth Olungu, Christine oth Gelderblom, Hans oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:152 year:2021 pages:26-40 extent:15 https://doi.org/10.1016/j.ejca.2021.04.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 152 2021 26-40 15 |
| spelling |
10.1016/j.ejca.2021.04.015 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica (DE-627)ELV054658233 (ELSEVIER)S0959-8049(21)00246-X DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Schöffski, Patrick verfasserin aut Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” 2021 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Elsevier Toulmonde, Maud oth Estival, Anna oth Marquina, Gloria oth Dudzisz-Śledź, Monika oth Brahmi, Mehdi oth Steeghs, Neeltje oth Karavasilis, Vasilios oth de Haan, Jacco oth Wozniak, Agnieszka oth Cousin, Sophie oth Domènech, Marta oth Bovée, Judith V.M.G. oth Charon-Barra, Céline oth Marreaud, Sandrine oth Litière, Saskia oth De Meulemeester, Laura oth Olungu, Christine oth Gelderblom, Hans oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:152 year:2021 pages:26-40 extent:15 https://doi.org/10.1016/j.ejca.2021.04.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 152 2021 26-40 15 |
| allfields_unstemmed |
10.1016/j.ejca.2021.04.015 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica (DE-627)ELV054658233 (ELSEVIER)S0959-8049(21)00246-X DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Schöffski, Patrick verfasserin aut Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” 2021 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Elsevier Toulmonde, Maud oth Estival, Anna oth Marquina, Gloria oth Dudzisz-Śledź, Monika oth Brahmi, Mehdi oth Steeghs, Neeltje oth Karavasilis, Vasilios oth de Haan, Jacco oth Wozniak, Agnieszka oth Cousin, Sophie oth Domènech, Marta oth Bovée, Judith V.M.G. oth Charon-Barra, Céline oth Marreaud, Sandrine oth Litière, Saskia oth De Meulemeester, Laura oth Olungu, Christine oth Gelderblom, Hans oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:152 year:2021 pages:26-40 extent:15 https://doi.org/10.1016/j.ejca.2021.04.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 152 2021 26-40 15 |
| allfieldsGer |
10.1016/j.ejca.2021.04.015 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica (DE-627)ELV054658233 (ELSEVIER)S0959-8049(21)00246-X DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Schöffski, Patrick verfasserin aut Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” 2021 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Elsevier Toulmonde, Maud oth Estival, Anna oth Marquina, Gloria oth Dudzisz-Śledź, Monika oth Brahmi, Mehdi oth Steeghs, Neeltje oth Karavasilis, Vasilios oth de Haan, Jacco oth Wozniak, Agnieszka oth Cousin, Sophie oth Domènech, Marta oth Bovée, Judith V.M.G. oth Charon-Barra, Céline oth Marreaud, Sandrine oth Litière, Saskia oth De Meulemeester, Laura oth Olungu, Christine oth Gelderblom, Hans oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:152 year:2021 pages:26-40 extent:15 https://doi.org/10.1016/j.ejca.2021.04.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 152 2021 26-40 15 |
| allfieldsSound |
10.1016/j.ejca.2021.04.015 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica (DE-627)ELV054658233 (ELSEVIER)S0959-8049(21)00246-X DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Schöffski, Patrick verfasserin aut Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” 2021 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Elsevier Toulmonde, Maud oth Estival, Anna oth Marquina, Gloria oth Dudzisz-Śledź, Monika oth Brahmi, Mehdi oth Steeghs, Neeltje oth Karavasilis, Vasilios oth de Haan, Jacco oth Wozniak, Agnieszka oth Cousin, Sophie oth Domènech, Marta oth Bovée, Judith V.M.G. oth Charon-Barra, Céline oth Marreaud, Sandrine oth Litière, Saskia oth De Meulemeester, Laura oth Olungu, Christine oth Gelderblom, Hans oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:152 year:2021 pages:26-40 extent:15 https://doi.org/10.1016/j.ejca.2021.04.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 152 2021 26-40 15 |
| language |
English |
| source |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:152 year:2021 pages:26-40 extent:15 |
| sourceStr |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:152 year:2021 pages:26-40 extent:15 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Chemotherapy Tyrosine kinase inhibitor Ifosfamide Soft tissue sarcoma Nintedanib Oral anticancer treatment Vascular endothelial growth factor receptor Fibroblast growth factor receptor |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| authorswithroles_txt_mv |
Schöffski, Patrick @@aut@@ Toulmonde, Maud @@oth@@ Estival, Anna @@oth@@ Marquina, Gloria @@oth@@ Dudzisz-Śledź, Monika @@oth@@ Brahmi, Mehdi @@oth@@ Steeghs, Neeltje @@oth@@ Karavasilis, Vasilios @@oth@@ de Haan, Jacco @@oth@@ Wozniak, Agnieszka @@oth@@ Cousin, Sophie @@oth@@ Domènech, Marta @@oth@@ Bovée, Judith V.M.G. @@oth@@ Charon-Barra, Céline @@oth@@ Marreaud, Sandrine @@oth@@ Litière, Saskia @@oth@@ De Meulemeester, Laura @@oth@@ Olungu, Christine @@oth@@ Gelderblom, Hans @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000241849 |
| dewey-sort |
3610 |
| id |
ELV054658233 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054658233</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624213145.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2021.04.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054658233</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(21)00246-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schöffski, Patrick</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tyrosine kinase inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ifosfamide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Soft tissue sarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nintedanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral anticancer treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vascular endothelial growth factor receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fibroblast growth factor receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toulmonde, Maud</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Estival, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marquina, Gloria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dudzisz-Śledź, Monika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brahmi, Mehdi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Steeghs, Neeltje</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karavasilis, Vasilios</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Haan, Jacco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wozniak, Agnieszka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cousin, Sophie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domènech, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bovée, Judith V.M.G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Charon-Barra, Céline</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marreaud, Sandrine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Litière, Saskia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Meulemeester, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olungu, Christine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gelderblom, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:152</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:26-40</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2021.04.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">152</subfield><subfield code="j">2021</subfield><subfield code="h">26-40</subfield><subfield code="g">15</subfield></datafield></record></collection>
|
| author |
Schöffski, Patrick |
| spellingShingle |
Schöffski, Patrick ddc 610 bkl 44.52 Elsevier Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” |
| authorStr |
Schöffski, Patrick |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000241849 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.52 bkl Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Chemotherapy Elsevier Tyrosine kinase inhibitor Elsevier Ifosfamide Elsevier Soft tissue sarcoma Elsevier Nintedanib Elsevier Oral anticancer treatment Elsevier Vascular endothelial growth factor receptor Elsevier Fibroblast growth factor receptor |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m t mt a e ae g m gm m d ś mdś m b mb n s ns v k vk h j d hj hjd a w aw s c sc m d md j v b jv jvb c c b ccb s m sm s l sl m l d ml mld c o co h g hg |
| hierarchy_parent_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| hierarchy_parent_id |
ELV000241849 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000241849 |
| title |
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” |
| ctrlnum |
(DE-627)ELV054658233 (ELSEVIER)S0959-8049(21)00246-X |
| title_full |
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” |
| author_sort |
Schöffski, Patrick |
| journal |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| journalStr |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
26 |
| author_browse |
Schöffski, Patrick |
| container_volume |
152 |
| physical |
15 |
| class |
610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Schöffski, Patrick |
| doi_str_mv |
10.1016/j.ejca.2021.04.015 |
| dewey-full |
610 |
| title_sort |
randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: eortc-1506-stbsg “anita” |
| title_auth |
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” |
| abstract |
EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. |
| abstractGer |
EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. |
| abstract_unstemmed |
EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” |
| url |
https://doi.org/10.1016/j.ejca.2021.04.015 |
| remote_bool |
true |
| author2 |
Toulmonde, Maud Estival, Anna Marquina, Gloria Dudzisz-Śledź, Monika Brahmi, Mehdi Steeghs, Neeltje Karavasilis, Vasilios de Haan, Jacco Wozniak, Agnieszka Cousin, Sophie Domènech, Marta Bovée, Judith V.M.G. Charon-Barra, Céline Marreaud, Sandrine Litière, Saskia De Meulemeester, Laura Olungu, Christine Gelderblom, Hans |
| author2Str |
Toulmonde, Maud Estival, Anna Marquina, Gloria Dudzisz-Śledź, Monika Brahmi, Mehdi Steeghs, Neeltje Karavasilis, Vasilios de Haan, Jacco Wozniak, Agnieszka Cousin, Sophie Domènech, Marta Bovée, Judith V.M.G. Charon-Barra, Céline Marreaud, Sandrine Litière, Saskia De Meulemeester, Laura Olungu, Christine Gelderblom, Hans |
| ppnlink |
ELV000241849 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejca.2021.04.015 |
| up_date |
2024-07-06T22:20:27.694Z |
| _version_ |
1803869935574712320 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054658233</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624213145.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2021.04.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001630.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054658233</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(21)00246-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schöffski, Patrick</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tyrosine kinase inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ifosfamide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Soft tissue sarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nintedanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral anticancer treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vascular endothelial growth factor receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fibroblast growth factor receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toulmonde, Maud</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Estival, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marquina, Gloria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dudzisz-Śledź, Monika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brahmi, Mehdi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Steeghs, Neeltje</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karavasilis, Vasilios</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Haan, Jacco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wozniak, Agnieszka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cousin, Sophie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domènech, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bovée, Judith V.M.G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Charon-Barra, Céline</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marreaud, Sandrine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Litière, Saskia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Meulemeester, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olungu, Christine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gelderblom, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:152</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:26-40</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2021.04.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">152</subfield><subfield code="j">2021</subfield><subfield code="h">26-40</subfield><subfield code="g">15</subfield></datafield></record></collection>
|
| score |
7.40172 |